309 related articles for article (PubMed ID: 33736856)
41. Extramedullary myeloid cell tumors in myelodysplastic-syndromes: not a true indication of impending acute myeloid leukemia.
Byrd JC; Edenfield WJ; Dow NS; Aylesworth C; Dawson N
Leuk Lymphoma; 1996 Mar; 21(1-2):153-9. PubMed ID: 8907283
[TBL] [Abstract][Full Text] [Related]
42. The efficacy and adverse events of venetoclax in combination with hypomethylating agents treatment for patients with acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis.
Liu B; Guo Y; Deng L; Qiao Y; Jian J
Hematology; 2020 Dec; 25(1):414-423. PubMed ID: 33191860
[TBL] [Abstract][Full Text] [Related]
43. Age related risk of myelodysplastic syndrome and acute myeloid leukemia among breast cancer survivors.
Kaplan HG; Malmgren JA; Li CI; Calip GS
Breast Cancer Res Treat; 2013 Dec; 142(3):629-36. PubMed ID: 24265034
[TBL] [Abstract][Full Text] [Related]
44. Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide.
Rollison DE; Shain KH; Lee JH; Hampras SS; Fulp W; Fisher K; Al Ali NH; Padron E; Lancet J; Xu Q; Olesnyckyj M; Kenvin L; Knight R; Dalton W; List A; Komrokji RS
Cancer Med; 2016 Jul; 5(7):1694-701. PubMed ID: 27098006
[TBL] [Abstract][Full Text] [Related]
45. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.
Tebbi CK; London WB; Friedman D; Villaluna D; De Alarcon PA; Constine LS; Mendenhall NP; Sposto R; Chauvenet A; Schwartz CL
J Clin Oncol; 2007 Feb; 25(5):493-500. PubMed ID: 17290056
[TBL] [Abstract][Full Text] [Related]
46. Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials.
Ruscito I; Bellati F; Ray-Coquard I; Mirza MR; du Bois A; Gasparri ML; Costanzi F; De Marco MP; Nuti M; Caserta D; Pignata S; Dorigo O; Sehouli J; Braicu EI
Cancer Treat Rev; 2020 Jul; 87():102040. PubMed ID: 32485510
[TBL] [Abstract][Full Text] [Related]
47. Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis.
Scholz M; Engert A; Franklin J; Josting A; Diehl V; Hasenclever D; Loeffler M
Ann Oncol; 2011 Mar; 22(3):681-688. PubMed ID: 20720088
[TBL] [Abstract][Full Text] [Related]
48. Therapy-related myelodysplastic syndrome with monosomy 5 after successful treatment of acute myeloid leukemia (M2).
Ogasawara T; Yasuyama M; Kawauchi K
Am J Hematol; 2005 Jun; 79(2):136-41. PubMed ID: 15929101
[TBL] [Abstract][Full Text] [Related]
49. Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience.
Tallman MS; Gray R; Bennett JM; Variakojis D; Robert N; Wood WC; Rowe JM; Wiernik PH
J Clin Oncol; 1995 Jul; 13(7):1557-63. PubMed ID: 7602344
[TBL] [Abstract][Full Text] [Related]
50. DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics.
Rabenau K; Hofstatter E
Clin Ther; 2016 Jul; 38(7):1577-88. PubMed ID: 27368114
[TBL] [Abstract][Full Text] [Related]
51. [Allo-HSCT for acute myeloid leukemia with myelodysplastic-related changes: a clinical analysis].
Zhang HX; Pang AM; Chen X; Zhang RL; Zhai WH; Ma QL; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):814-822. PubMed ID: 34788920
[No Abstract] [Full Text] [Related]
52. Maximizing Breast Cancer Therapy with Awareness of Potential Treatment-Related Blood Disorders.
Kaplan HG; Calip GS; Malmgren JA
Oncologist; 2020 May; 25(5):391-397. PubMed ID: 32073195
[TBL] [Abstract][Full Text] [Related]
53. Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials.
Koontz MZ; Horning SJ; Balise R; Greenberg PL; Rosenberg SA; Hoppe RT; Advani RH
J Clin Oncol; 2013 Feb; 31(5):592-8. PubMed ID: 23295809
[TBL] [Abstract][Full Text] [Related]
54. Chemical exposures and risk of acute myeloid leukemia and myelodysplastic syndromes in a population-based study.
Poynter JN; Richardson M; Roesler M; Blair CK; Hirsch B; Nguyen P; Cioc A; Cerhan JR; Warlick E
Int J Cancer; 2017 Jan; 140(1):23-33. PubMed ID: 27603749
[TBL] [Abstract][Full Text] [Related]
55. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series.
Pedersen-Bjergaard J; Philip P; Larsen SO; Andersson M; Daugaard G; Ersbøll J; Hansen SW; Hou-Jensen K; Nielsen D; Sigsgaard TC
Leukemia; 1993 Dec; 7(12):1975-86. PubMed ID: 8255096
[TBL] [Abstract][Full Text] [Related]
56. [Efficacy and Safety of Decitabine Combined with CAG (Cytarabine, Aclarubicin, G-CSF) for Patients with Intermediate or High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: a Meta-Analysis].
Zhang JL; Cao YP; Li JG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):494-503. PubMed ID: 30998160
[TBL] [Abstract][Full Text] [Related]
57. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms.
Björkholm M; Derolf AR; Hultcrantz M; Kristinsson SY; Ekstrand C; Goldin LR; Andreasson B; Birgegård G; Linder O; Malm C; Markevärn B; Nilsson L; Samuelsson J; Granath F; Landgren O
J Clin Oncol; 2011 Jun; 29(17):2410-5. PubMed ID: 21537037
[TBL] [Abstract][Full Text] [Related]
58. Hematological disorders after salvage PARPi treatment for ovarian cancer: Cytogenetic and molecular defects and clinical outcomes.
Todisco E; Gigli F; Ronchini C; Amato V; Sammassimo S; Pastano R; Parma G; Lapresa MT; Bertolini F; Corsini C; Gregato G; Poletti C; Pelicci PG; Alcalay M; Colombo N; Tarella C
Int J Cancer; 2022 Nov; 151(10):1791-1803. PubMed ID: 35695283
[TBL] [Abstract][Full Text] [Related]
59. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
Steensma DP; Abedi M; Bejar R; Cogle CR; Foucar K; Garcia-Manero G; George TI; Grinblatt D; Komrokji R; Ma X; Maciejewski J; Pollyea DA; Savona MR; Scott B; Sekeres MA; Thompson MA; Swern AS; Nifenecker M; Sugrue MM; Erba H
BMC Cancer; 2016 Aug; 16():652. PubMed ID: 27538433
[TBL] [Abstract][Full Text] [Related]
60. Familial aggregation of acute myeloid leukemia and myelodysplastic syndromes.
Goldin LR; Kristinsson SY; Liang XS; Derolf AR; Landgren O; Björkholm M
J Clin Oncol; 2012 Jan; 30(2):179-83. PubMed ID: 22162584
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
